Cargando…

The role of RB1 alteration and 4q12 amplification in IDH-WT glioblastoma

BACKGROUND: Recent studies have identified that glioblastoma IDH-wildtype (GBM IDH-WT) might be comprised of molecular subgroups with distinct prognoses. Therefore, we investigated the correlation between genetic alterations and survival in 282 GBM IDH-WT patients, to identify subgroups with distinc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dono, Antonio, Ramesh, Arvind V, Wang, Emily, Shah, Mauli, Tandon, Nitin, Ballester, Leomar Y, Esquenazi, Yoshua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193911/ https://www.ncbi.nlm.nih.gov/pubmed/34131647 http://dx.doi.org/10.1093/noajnl/vdab050

Ejemplares similares

OTHR-06. ANALYSIS OF GENOMIC ALTERATIONS IN 154 BRAIN METASTASES
por: Ostorga, Antonio Dono, et al.
Publicado: (2019)

Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors
por: Takayasu, Takeshi, et al.
Publicado: (2020)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

SDPS-44 RAPID DETECTION OF MUTATIONS IN CSF-CFTNA WITH THE GENEXUS INTEGRATED SEQUENCER
por: Arjuna, Srividya, et al.
Publicado: (2023)

Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse
por: Arevalo, Octavio D., et al.
Publicado: (2019)

Glioma and the gut–brain axis: opportunities and future perspectives
por: Dono, Antonio, et al.
Publicado: (2022)

Glioma induced alterations in fecal short-chain fatty acids and neurotransmitters
por: Dono, Antonio, et al.
Publicado: (2020)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Glioma and temozolomide induced alterations in gut microbiome
por: Patrizz, Anthony, et al.
Publicado: (2020)

Traumatic rupture of an intracranial dermoid cyst: Case report and literature review
por: Esquenazi, Yoshua, et al.
Publicado: (2013)

Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma
por: Zorofchian, Soheil, et al.
Publicado: (2018)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma
por: Ma, Sirui, et al.
Publicado: (2020)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways
por: Avci, Naze G., et al.
Publicado: (2020)

RADI-05. Metastatic Neoplasm Volume Kinetics Following Two-Staged Stereotactic Radiosurgery
por: Damron, Ethan, et al.
Publicado: (2021)

Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2023)

High FREM2 Gene and Protein Expression Are Associated with Favorable Prognosis of IDH-WT Glioblastomas
por: Jovčevska, Ivana, et al.
Publicado: (2019)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2022)

EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco
por: Senhaji, Nadia, et al.
Publicado: (2017)

Multiregional Sequencing of IDH-WT Glioblastoma Reveals High Genetic Heterogeneity and a Dynamic Evolutionary History
por: Franceschi, Sara, et al.
Publicado: (2021)

Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
por: Kurdi, Maher, et al.
Publicado: (2021)

Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
por: Bagley, Stephen J, et al.
Publicado: (2021)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma
por: Kaye, Brandon, et al.
Publicado: (2023)

TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma
por: Kikuchi, Zensho, et al.
Publicado: (2020)

Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
por: de Groot, John F, et al.
Publicado: (2022)

Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomes
por: Zhang, Yalan, et al.
Publicado: (2022)

A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma
por: Ghosh, Subhajit, et al.
Publicado: (2023)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors
por: Ballester, Leomar Y., et al.
Publicado: (2018)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation
por: Barresi, Valeria, et al.
Publicado: (2021)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

Creutzfeldt Cell Rich Glioblastoma: A Diagnostic Dilemma
por: Boghani, Zain, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iirofjcj7qagjb6rhni7maff1j